Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip...
Transcript of Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip...
![Page 1: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/1.jpg)
Britta Kaltoft, Herlev HospitalPhilip Blach Rossen, Århus Sygehus
Hotel Hilton, 17. juni
![Page 2: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/2.jpg)
• Gastrointestinal Stromal Tumor (GIST)
• Soft Tissue Sarcoma (STS)
• Osteosarcoma (OS)
• 64 posters, 29 poster discussions, 9 oral presentations, 1 plenary session
![Page 3: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/3.jpg)
![Page 4: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/4.jpg)
Study hypothesis:
Three years of adjuvant imatinib may result in longer Recurrence Free Survival (RFS) aslonger Recurrence Free Survival (RFS) as compared to one year of imatinib
![Page 5: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/5.jpg)
The ATP binding pocket of the KIT kinase domain
Kinase
of the KIT kinase domain is occupied by imatinib1
Signaling is inhibited by domainsprevention of substrate
phosphorylation1
With signaling inhibited,P
PP PATP
With signaling inhibited, proliferation and survival are interrupted1,2
PP P
SIGNALING
Imatinibmesylate
SIGNALING
1. Savage DG et al. N Engl J Med. 2002;346:683-693.
2. Scheijen B et al. Oncogene. 2002;21:3314-3333.
![Page 6: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/6.jpg)
80–85% 5–7%KIT PDGFR-αOverall mutation frequency: 87.4%
← MembraneExon 9 (11%)
Exon 11 (67.5%)Exon 13 (0.9%)
Exon 12 (0.9%)Exon 14 (0.3%)
Cytoplasm
Exon 17 (0.5%) Exon 18 (6.3%)
Gain of function mutations result in abnormal constitutively activatedGain-of-function mutations result in abnormal, constitutively activated receptor tyrosine kinase activityLigand-independent mitogenic activityStimulation of downstream signaling pathwaysStimulation of downstream signaling pathways
1. Heinrich et al. Hum Pathol. 2002;33:484.2. Corless et al. Proc Am Assoc Cancer Res. 2003;44. Abstract R4447.
![Page 7: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/7.jpg)
![Page 8: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/8.jpg)
Objectives:
• Primary: RFSTime from randomization to GIST recurrenceTime from randomization to GIST recurrence or death
• Secondary:Safety and overall survival
![Page 9: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/9.jpg)
Inclusion criteria:• Histologically confirmed
GIST d KIT iti
Exclusion criteria:• Inoperable, recurrent or
t t ti GIST *GIST and KIT-positive• High risk recurrence risk
(consensus criteria):
metastatic GIST *• Age < 18
ECOG PS 2(consensus criteria):- Diameter > 10 cm or
Tumor mitosis count >
• ECOG PS > 2• > 12 weeks between
date of surgery and- Tumor mitosis count > 10/50 HPF or- Tumor rupture
date of surgery and study entry
• Clinically significant- Tumor rupture • Clinically significant cardiac, hepatic, renal and bone marrow disease
![Page 10: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/10.jpg)
![Page 11: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/11.jpg)
![Page 12: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/12.jpg)
![Page 13: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/13.jpg)
Conclusion:
• One vs three years of imatinib improves RFSOne vs three years of imatinib improves RFS and OS
• Relatively well tolerated
• How would RFS and OS have been without the R1-group (tumor rupture)?
• Which patients? How long?
![Page 14: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/14.jpg)
![Page 15: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/15.jpg)
• Inhibits KIT, PDGFR, FGFR, VEGFR 2,3, TIE-2 and B-RAF
• Approximately 24 hours half-lives
• Primary objective:Clinical Benefit Rate (CR, PR or durable SD)
• Secondary objective:ORR, PFR, OS, Safety
• 160 mg once daily day 1-21 of a 28-days cycle
![Page 16: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/16.jpg)
![Page 17: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/17.jpg)
![Page 18: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/18.jpg)
![Page 19: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/19.jpg)
![Page 20: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/20.jpg)
![Page 21: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/21.jpg)
• Adverse Events (all grades):Fatigue, Hand Foot Skin Reaction and gHypertension
• Adverse Events (grade 3-4):Hypertension Hand Foot Skin Reaction andHypertension, Hand Foot Skin Reaction and Hypophosphatemia
![Page 22: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/22.jpg)
Conclusion:
Activity of regorafenib in patients with advanced GIST following failure of both IM and SUGIST following failure of both IM and SU
![Page 23: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/23.jpg)
![Page 24: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/24.jpg)
![Page 25: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/25.jpg)
![Page 26: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/26.jpg)
• A multikinase angionesis inhibitor targeting VEGFR, PDGFR and c-KIT
• Prior phase II study was promissing withPrior phase II study was promissing with acceptable toxicity profile, although insufficient activity in adipocytic sarcomasactivity in adipocytic sarcomas
![Page 27: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/27.jpg)
Multicenter study: 4 continents, 13 countries, 72 institutions19 patients still on protocol therapy
![Page 28: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/28.jpg)
Inclusion criteriaAge > 18 WHO PS 0 1 Including histology criteria• Age > 18, WHO PS 0-1
• PD during the last sixmonths (or 12 months in
Including histology criteria• Fibroblastic• Fibrohistocyticmonths (or 12 months in
case of (neo)-adjuvanttreatment only)
y• Leiomyosarcoma• Synovial sarcoma
• Up to four lines of prior treatment (includinganthracycline)
• MPNST• NOSanthracycline)
• RECIST 1.0 measurable• Angiogenesis inhibitor-
• Vascular STS• Malignant glomus tumorsg g
naive• Adequate major organ
f ifunction• No poorly controlled
hypertension bleedinghypertension, bleedingdiathesis or CNS involvement
![Page 29: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/29.jpg)
![Page 30: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/30.jpg)
![Page 31: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/31.jpg)
![Page 32: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/32.jpg)
![Page 33: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/33.jpg)
Grade 3 in pazopanib-group: • Fatigue (13 %)• Hypertension (16%)• Anorexia (14%)• Diarrhea (11%)• Affected liver chemistry (4-30%)
Other:• Myocardial dysfunction (5 vs 10%)• Venous tromboembolic (5 vs 18%)• Pneumothorax (0 vs 8%)
![Page 34: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/34.jpg)
Conclusion:
Pazopanib is an active drug in pretreated metastatic STS patients improving PFS 3-foldmetastatic STS patients improving PFS 3-fold
Adverse Events are manageable
Final OS analysis is anticipated in 2011
![Page 35: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/35.jpg)
• Focus on PFS > OS
• Imatinib as adjuvant treatment; which patients? And how long?patients? And how long?
Further knowledge on subgroups; which• Further knowledge on subgroups; which patients should have treatment?
• Pazopanib, regorafenib; other ib’s, ab’s and mus’s
![Page 36: Britta Kaltoft, Herlev Hospital Philip Blach Rossen, … · Britta Kaltoft, Herlev Hospital Philip Blach Rossen, ... The ATP binding pocket of the KIT kinase domain ... • RECIST](https://reader030.fdocuments.net/reader030/viewer/2022021622/5b93778709d3f206218d74f2/html5/thumbnails/36.jpg)
Questions